Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise.

Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S.

Nat Rev Clin Oncol. 2019 Sep 30. doi: 10.1038/s41571-019-0267-4. [Epub ahead of print] Review.

PMID:
31570827
2.

Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade.

Belcaid L, Garaud S, Kerger J, Spyridon S, Aspeslagh S.

Acta Clin Belg. 2019 Sep 7:1-5. doi: 10.1080/17843286.2019.1664051. [Epub ahead of print]

PMID:
31495282
3.

Is There Room for Immune Checkpoint Inhibitors in Patients Who Have NSCLC With Autoimmune Diseases?

Remon J, Hendriks L, Aspeslagh S, Besse B.

J Thorac Oncol. 2019 Oct;14(10):1701-1703. doi: 10.1016/j.jtho.2019.07.004. Epub 2019 Aug 13. No abstract available.

PMID:
31420287
4.

Treatment duration of checkpoint inhibitors for NSCLC.

Remon J, Menis J, Aspeslagh S, Besse B.

Lancet Respir Med. 2019 Oct;7(10):835-837. doi: 10.1016/S2213-2600(19)30192-4. Epub 2019 Aug 7. No abstract available.

PMID:
31401050
5.

How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?

Castelo-Branco L, Aspeslagh S, Kotecki N, Awada A.

Curr Opin Oncol. 2019 Sep;31(5):420-423. doi: 10.1097/CCO.0000000000000563.

PMID:
31335831
6.

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.

de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, Gorus F, Roep BO, Aspeslagh S, Neyns B, Velkeniers B, Kharagjitsingh AV.

Eur J Endocrinol. 2019 Jul 1. pii: EJE-19-0291.R1. doi: 10.1530/EJE-19-0291. [Epub ahead of print]

7.

PRIMMO study protocol: a phase II study combining PD-1 blockade, radiation and immunomodulation to tackle cervical and uterine cancer.

Tuyaerts S, Van Nuffel AMT, Naert E, Van Dam PA, Vuylsteke P, De Caluwé A, Aspeslagh S, Dirix P, Lippens L, De Jaeghere E, Amant F, Vandecasteele K, Denys H.

BMC Cancer. 2019 May 28;19(1):506. doi: 10.1186/s12885-019-5676-3.

8.

Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?

De Bruyn P, Van Gestel D, Ost P, Kruse V, Brochez L, Van Vlierberghe H, Devresse A, Del Marmol V, Le Moine A, Aspeslagh S.

Curr Opin Oncol. 2019 Mar;31(2):54-64. doi: 10.1097/CCO.0000000000000505.

PMID:
30694841
9.

Cancer immunotherapy-associated hypophysitis.

Solinas C, Porcu M, De Silva P, Musi M, Aspeslagh S, Scartozzi M, Willard-Gallo K, Mariotti S, Saba L.

Semin Oncol. 2018 Jun;45(3):181-186. doi: 10.1053/j.seminoncol.2018.09.002. Epub 2018 Oct 21. Review.

PMID:
30352754
10.

Long-Term Survival in Patients Responding to Anti-PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation.

Gauci ML, Lanoy E, Champiat S, Caramella C, Ammari S, Aspeslagh S, Varga A, Baldini C, Bahleda R, Gazzah A, Michot JM, Postel-Vinay S, Angevin E, Ribrag V, Hollebecque A, Soria JC, Robert C, Massard C, Marabelle A.

Clin Cancer Res. 2019 Feb 1;25(3):946-956. doi: 10.1158/1078-0432.CCR-18-0793. Epub 2018 Oct 8.

PMID:
30297458
11.

Importance of choice of materials and methods in PD-L1 and TIL assessment in oropharyngeal squamous cell carcinoma.

De Meulenaere A, Vermassen T, Creytens D, Aspeslagh S, Deron P, Duprez F, Rottey S, Van Dorpe JA, Ferdinande L.

Histopathology. 2018 Sep;73(3):500-509. doi: 10.1111/his.13650. Epub 2018 Jul 4.

PMID:
29768723
12.

Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours.

Herin H, Aspeslagh S, Castanon E, Dyevre V, Marabelle A, Varga A, Postel Vinay S, Michot JM, Ribrag V, Gazzah A, Bahleda R, Mir O, Massard C, Hollebecque A, Soria JC, Baldini C.

Eur J Cancer. 2018 May;95:68-74. doi: 10.1016/j.ejca.2018.03.002. Epub 2018 Apr 7.

PMID:
29635146
13.

Epigenetic modifiers as new immunomodulatory therapies in solid tumours.

Aspeslagh S, Morel D, Soria JC, Postel-Vinay S.

Ann Oncol. 2018 Apr 1;29(4):812-824. doi: 10.1093/annonc/mdy050.

PMID:
29432557
14.

Immuno-oncology-101: overview of major concepts and translational perspectives.

Allard B, Aspeslagh S, Garaud S, Dupont FA, Solinas C, Kok M, Routy B, Sotiriou C, Stagg J, Buisseret L.

Semin Cancer Biol. 2018 Oct;52(Pt 2):1-11. doi: 10.1016/j.semcancer.2018.02.005. Epub 2018 Feb 8. Review.

PMID:
29428479
15.

Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.

Danlos FX, Voisin AL, Dyevre V, Michot JM, Routier E, Taillade L, Champiat S, Aspeslagh S, Haroche J, Albiges L, Massard C, Girard N, Dalle S, Besse B, Laghouati S, Soria JC, Mateus C, Robert C, Lanoy E, Marabelle A, Lambotte O.

Eur J Cancer. 2018 Mar;91:21-29. doi: 10.1016/j.ejca.2017.12.008. Epub 2018 Jan 10.

PMID:
29331748
16.

In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?

Aspeslagh S, Matias M, Palomar V, Dercle L, Lanoy E, Soria JC, Postel-Vinay S.

Eur J Cancer. 2017 Dec;87:65-74. doi: 10.1016/j.ejca.2017.09.027. Epub 2017 Nov 7.

PMID:
29126088
17.

Tumor PD-L1 status and CD8+ tumor-infiltrating T cells: markers of improved prognosis in oropharyngeal cancer.

De Meulenaere A, Vermassen T, Aspeslagh S, Deron P, Duprez F, Laukens D, Van Dorpe J, Ferdinande L, Rottey S.

Oncotarget. 2017 Jul 6;8(46):80443-80452. doi: 10.18632/oncotarget.19045. eCollection 2017 Oct 6.

18.

Challenges and perspectives in the immunotherapy of Hodgkin lymphoma.

Michot JM, Lazarovici J, Ghez D, Danu A, Fermé C, Bigorgne A, Ribrag V, Marabelle A, Aspeslagh S.

Eur J Cancer. 2017 Nov;85:67-77. doi: 10.1016/j.ejca.2017.08.014. Epub 2017 Sep 9. Review.

PMID:
28892775
19.

Are phase I trials safe for older patients?

Baldini C, Le Saux O, Helissey C, Aspeslagh S, Castanon E, Varga A, Gazzah A, Bahleda R, Mir O, Massard C, Soria JC, Hollebecque A.

J Geriatr Oncol. 2018 Mar;9(2):87-92. doi: 10.1016/j.jgo.2017.08.012. Epub 2017 Sep 8. Review.

PMID:
28890328
20.

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

Bigot F, Castanon E, Baldini C, Hollebecque A, Carmona A, Postel-Vinay S, Angevin E, Armand JP, Ribrag V, Aspeslagh S, Varga A, Bahleda R, Menis J, Gazzah A, Michot JM, Marabelle A, Soria JC, Massard C.

Eur J Cancer. 2017 Oct;84:212-218. doi: 10.1016/j.ejca.2017.07.027. Epub 2017 Aug 18.

PMID:
28826074
21.

Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors).

Sun R, Champiat S, Dercle L, Aspeslagh S, Castanon E, Limkin EJ, Baldini C, Postel-Vinay S, Hollebecque A, Massard C, Ammari S, Deutsch E, Soria JC, Marabelle A, Ferté C.

Eur J Cancer. 2017 Oct;84:202-211. doi: 10.1016/j.ejca.2017.07.033. Epub 2017 Aug 18.

PMID:
28826073
22.

RECIST response and variation of circulating tumour cells in phase 1 trials: A prospective multicentric study.

Massard C, Borget I, Farace F, Aspeslagh S, Le Deley MC, Le Tourneau C, Bidard FC, Pierga JY, Dieras V, Hofman P, Spano JP, Ferte C, Lacroix L, Soria JC.

Eur J Cancer. 2017 Sep;83:185-193. doi: 10.1016/j.ejca.2017.05.016. Epub 2017 Jul 22.

PMID:
28743036
23.

Turning the tide: Clinical utility of PD-L1 expression in squamous cell carcinoma of the head and neck.

De Meulenaere A, Vermassen T, Aspeslagh S, Huvenne W, Van Dorpe J, Ferdinande L, Rottey S.

Oral Oncol. 2017 Jul;70:34-42. doi: 10.1016/j.oraloncology.2017.05.002. Epub 2017 May 19. Review.

PMID:
28622889
24.

[What is the place of the combinations for immunotherapy with chemotherapy or with other immune checkpoint inhibitors?]

Douchet G, Aspeslagh S.

Bull Cancer. 2017 May;104(5):485-493. doi: 10.1016/j.bulcan.2017.03.008. Epub 2017 Apr 19. Review. French.

PMID:
28433197
25.

Prognostic markers in oropharyngeal squamous cell carcinoma: focus on CD70 and tumour infiltrating lymphocytes.

De Meulenaere A, Vermassen T, Aspeslagh S, Zwaenepoel K, Deron P, Duprez F, Rottey S, Ferdinande L.

Pathology. 2017 Jun;49(4):397-404. doi: 10.1016/j.pathol.2017.02.002. Epub 2017 Apr 17.

PMID:
28427753
26.

Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.

Aspeslagh S, Shailubhai K, Bahleda R, Gazzah A, Varga A, Hollebecque A, Massard C, Spreafico A, Reni M, Soria JC.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1257-1265. doi: 10.1007/s00280-017-3303-z. Epub 2017 Apr 19.

PMID:
28424962
27.

Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy.

Le Burel S, Champiat S, Routier E, Aspeslagh S, Albiges L, Szwebel TA, Michot JM, Chretien P, Mariette X, Voisin AL, Lambotte O.

Ann Rheum Dis. 2018 Mar;77(3):468-470. doi: 10.1136/annrheumdis-2016-210820. Epub 2017 Feb 27. No abstract available.

PMID:
28242618
28.

NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients.

Rusakiewicz S, Perier A, Semeraro M, Pitt JM, Pogge von Strandmann E, Reiners KS, Aspeslagh S, Pipéroglou C, Vély F, Ivagnes A, Jegou S, Halama N, Chaigneau L, Validire P, Christidis C, Perniceni T, Landi B, Berger A, Isambert N, Domont J, Bonvalot S, Terrier P, Adam J, Coindre JM, Emile JF, Poirier-Colame V, Chaba K, Rocha B, Caignard A, Toubert A, Enot D, Koch J, Marabelle A, Lambert M, Caillat-Zucman S, Leyvraz S, Auclair C, Vivier E, Eggermont A, Borg C, Blay JY, Le Cesne A, Mir O, Zitvogel L.

Oncoimmunology. 2016 Apr 25;6(1):e1137418. doi: 10.1080/2162402X.2015.1137418. eCollection 2017.

29.

JAK Mutations as Escape Mechanisms to Anti-PD-1 Therapy.

Marabelle A, Aspeslagh S, Postel-Vinay S, Soria JC.

Cancer Discov. 2017 Feb;7(2):128-130. doi: 10.1158/2159-8290.CD-16-1439.

30.

TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?

De Meulenaere A, Vermassen T, Aspeslagh S, Vandecasteele K, Rottey S, Ferdinande L.

Head Neck Pathol. 2017 Sep;11(3):354-363. doi: 10.1007/s12105-016-0776-8. Epub 2016 Dec 28. Review.

31.

Cancer immunotherapy: from the lab to clinical applications-Potential impact on cancer centres' organisation.

Cairns L, Aspeslagh S, Anichini A, Kyte JA, Blank C, Ascierto P, Rekers N, Straten PT, Awada A.

Ecancermedicalscience. 2016 Nov 10;10:691. eCollection 2016.

32.

3D waterfall plots: a better graphical representation of tumor response in oncology.

Castanon Alvarez E, Aspeslagh S, Soria JC.

Ann Oncol. 2017 Mar 1;28(3):454-456. doi: 10.1093/annonc/mdw656. No abstract available.

PMID:
27993798
33.

Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.

Aspeslagh S, Stein M, Bahleda R, Hollebecque A, Salles G, Gyan E, Fudio S, Extremera S, Alfaro V, Soto-Matos A, Soria JC.

Anticancer Drugs. 2017 Mar;28(3):341-349. doi: 10.1097/CAD.0000000000000457.

PMID:
27977433
34.

Phase I dose-escalation study of plitidepsin in combination with bevacizumab in patients with refractory solid tumors.

Aspeslagh S, Awada A, S Matos-Pita A, Aftimos P, Bahleda R, Varga A, Soria JC.

Anticancer Drugs. 2016 Nov;27(10):1021-7. doi: 10.1097/CAD.0000000000000409.

PMID:
27610894
35.

Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy.

Dercle L, Ammari S, Champiat S, Massard C, Ferté C, Taihi L, Seban RD, Aspeslagh S, Mahjoubi L, Kamsu-Kom N, Robert C, Marabelle A, Schlumberger M, Soria JC, Postel-Vinay S.

Eur J Cancer. 2016 Sep;65:33-42. doi: 10.1016/j.ejca.2016.05.031. Epub 2016 Jul 21.

PMID:
27451022
36.

CD70 Expression and Its Correlation with Clinicopathological Variables in Squamous Cell Carcinoma of the Head and Neck.

De Meulenaere A, Vermassen T, Aspeslagh S, Zwaenepoel K, Deron P, Duprez F, Ferdinande L, Rottey S.

Pathobiology. 2016;83(6):327-33. doi: 10.1159/000446569. Epub 2016 Jul 8.

37.

Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.

Benderra MA, Aspeslagh S, Postel-Vinay S, Bigot L, De Baere T, Loriot Y, Lacroix L, Massard C, Vassal G, André F, Soria JC.

J Thorac Oncol. 2016 Feb;11(2):e21-3. doi: 10.1016/j.jtho.2015.08.001. Epub 2015 Dec 18. No abstract available.

38.

Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.

Aspeslagh S, Marabelle A, Soria JC, Armand JP.

Chin Clin Oncol. 2015 Dec;4(4):48. doi: 10.3978/j.issn.2304-3865.2015.12.06. Review.

39.

Rationale for anti-OX40 cancer immunotherapy.

Aspeslagh S, Postel-Vinay S, Rusakiewicz S, Soria JC, Zitvogel L, Marabelle A.

Eur J Cancer. 2016 Jan;52:50-66. doi: 10.1016/j.ejca.2015.08.021. Epub 2015 Nov 30. Review.

PMID:
26645943
40.

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies.

Postel-Vinay S, Aspeslagh S, Lanoy E, Robert C, Soria JC, Marabelle A.

Ann Oncol. 2016 Feb;27(2):214-24. doi: 10.1093/annonc/mdv550. Epub 2015 Nov 16. Review.

PMID:
26578728
41.

Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists.

Guillaume J, Pauwels N, Aspeslagh S, Zajonc DM, Elewaut D, Van Calenbergh S.

Bioorg Med Chem. 2015 Jul 1;23(13):3175-82. doi: 10.1016/j.bmc.2015.04.068. Epub 2015 May 4.

42.

An in silico approach for modelling T-helper polarizing iNKT cell agonists.

De Spiegeleer A, Wynendaele E, Vandekerckhove M, Stalmans S, Boucart M, Van Den Noortgate N, Venken K, Van Calenbergh S, Aspeslagh S, Elewaut D.

PLoS One. 2014 Jan 31;9(1):e87000. doi: 10.1371/journal.pone.0087000. eCollection 2014.

43.

Enhanced TCR footprint by a novel glycolipid increases NKT-dependent tumor protection.

Aspeslagh S, Nemčovič M, Pauwels N, Venken K, Wang J, Calenbergh SV, Zajonc DM, Elewaut D.

J Immunol. 2013 Sep 15;191(6):2916-25. doi: 10.4049/jimmunol.1203134. Epub 2013 Aug 19.

44.

Bacterial CD1d-restricted glycolipids induce IL-10 production by human regulatory T cells upon cross-talk with invariant NKT cells.

Venken K, Decruy T, Aspeslagh S, Van Calenbergh S, Lambrecht BN, Elewaut D.

J Immunol. 2013 Sep 1;191(5):2174-83. doi: 10.4049/jimmunol.1300562. Epub 2013 Jul 29.

45.

Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model.

Nur H, Fostier K, Aspeslagh S, Renmans W, Bertrand E, Leleu X, Favreau M, Breckpot K, Schots R, De Waele M, Van Valckenborgh E, De Bruyne E, Facon T, Elewaut D, Vanderkerken K, Menu E.

PLoS One. 2013 May 31;8(5):e65075. doi: 10.1371/journal.pone.0065075. Print 2013.

46.

Synthesis of 6"-triazole-substituted α-GalCer analogues as potent iNKT cell stimulating ligands.

Pauwels N, Aspeslagh S, Elewaut D, Van Calenbergh S.

Bioorg Med Chem. 2012 Dec 15;20(24):7149-54. doi: 10.1016/j.bmc.2012.09.063. Epub 2012 Oct 12.

PMID:
23122935
47.

Activated iNKT cells promote memory CD8+ T cell differentiation during viral infection.

Reilly EC, Thompson EA, Aspeslagh S, Wands JR, Elewaut D, Brossay L.

PLoS One. 2012;7(5):e37991. doi: 10.1371/journal.pone.0037991. Epub 2012 May 23.

48.

Divergent synthetic approach to 6''-modified α-GalCer analogues.

Pauwels N, Aspeslagh S, Vanhoenacker G, Sandra K, Yu ED, Zajonc DM, Elewaut D, Linclau B, Van Calenbergh S.

Org Biomol Chem. 2011 Dec 21;9(24):8413-21. doi: 10.1039/c1ob06235b. Epub 2011 Nov 1.

49.

Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis.

Aspeslagh S, Li Y, Yu ED, Pauwels N, Trappeniers M, Girardi E, Decruy T, Van Beneden K, Venken K, Drennan M, Leybaert L, Wang J, Franck RW, Van Calenbergh S, Zajonc DM, Elewaut D.

EMBO J. 2011 Jun 1;30(11):2294-305. doi: 10.1038/emboj.2011.145. Epub 2011 May 6.

50.

Synthesis and evaluation of amino-modified alpha-GalCer analogues.

Trappeniers M, Chofor R, Aspeslagh S, Li Y, Linclau B, Zajonc DM, Elewaut D, Van Calenbergh S.

Org Lett. 2010 Jul 2;12(13):2928-31. doi: 10.1021/ol100934z.

Supplemental Content

Loading ...
Support Center